The US Pharmaceutical Market Outlook To 2014: Market trends, leading players
and forecasts
Publisher:
Business
Insights
Report Description
This report provides comprehensive coverage of the US pharma market,
incorporating the market structure, pricing and regulation, in addition to
detailed analysis of leading companies and potential healthcare reforms.
This report assesses the marketed product portfolios, R&D pipelines, market
share data, sales forecasts and competitive landscape of the major players
in the US market. It highlights the key market and R&D trends that may
influence treatment sales with a thorough analysis of the competitive
dynamics of leading brands within each indication. This report also
identifies growth trends and developments for key drug classes and leading
players through to 2014.
>> More Info and Purchase
R&D Cost Cutting: Managing cost containment and safeguarding productivity
Publisher:
Business
Insights
Report Description
For several years, drug developers have been under intense pressure to
introduce new products in an environment of escalating R&D costs,
blockbuster patent expiration and resulting generic competition,
increasingly complex science, heightened regulatory scrutiny, and other
pressures. Now, however, the global economic meltdown has added new
imperatives for drug makers to cut costs. While expense reductions had
previously been centered on manufacturing, purchasing, administration and
sales operations, R&D is now included in these efforts. For the first
time, budgets are being pared, R&D groups are being streamlined, research
facilities are being closed and the research function, in general, is being
downsized. The most successful of these efforts enhance (or do not
significantly reduce) R&D productivity while the least successful cut costs
at the expense of future product introductions. Throughout 2008,
pharmas and biotechs have implemented a variety of initiatives to reduce R&D
budgets. These programs are expected to continue through the
foreseeable future with particularly heavy activity in the near term.
This report provides an analysis of these activities, with examples of major
R&D cost cutting initiatives and analysis of success probability.
>> More Info and Purchase
The Future of Biobanks: Regulation, ethics, investment and the humanization
of drug discovery
Publisher:
Business
Insights
Report Description
Biobanks collect and store human biospecimens, playing a vital role in
the development of novel drugs and diagnostics. In recent years, large
population-based biobanks have been established which monitor the health
status of participants over time to assess the natural occurrence and
progression of common diseases. Hundreds of disease-based biobanks are
located around the world, which are a valuable resource for biomarker
discovery as well as for studying progression, mortality and responses to
treatment. ‘The Future of Biobanks’ is a report published by Business
Insights that examines major trends in the biobanking industry and
identifies the key initiatives to upgrade the biobanking infrastructure.
This report explores the applications of biobanks and provides examples of
how large sets of high-quality biosamples are creating new ways to diagnose,
prevent and treat diseases. The activities of over 180 US biobanks are
assessed to illustrate how the scale and scope of biobanking is changing.
This report also evaluates the limitations of biobanks, in addition to
reviewing the unique legal, regulatory and ethical issues that surround this
new frontier of biomolecular research.
>> More Info and Purchase
The Top 10 Contract Research Organizations: Positioning, performance and
SWOT analyses
Publisher:
Business
Insights
Report Description
Cost containment and regulatory pressures within the pharma industry are
driving R&D outsourcing across the globe. Clinical obstacles to
approval have become more significant due to the growing availability of
existing generic treatments, and the trend to adopt Health Economics
Outcomes Research (HEOR) assessments is increasing the complexity of
clinical research. As a result, the scope of the CRO industry is
expanding, and the global market is predicted to value $35bn by 2013.
‘The Top 10 Contract Research Organizations’ is a report published by
Business Insights that examines the competitive landscape of the global CRO
industry. The latest key issues and evolving business models in the
CRO market are identified and the leading companies in this sector are
profiled in detail. For each of the top 10 CRO companies, this report
provides a detailed examination of financial performance by business segment
and growth strategies in the form of key acquisitions and divestments.
The opportunities and threats facing each of these leading players are also
assessed. This report also examines the size and growth of the global
CRO industry, with analysis of major market drivers and trends in CRO
destinations.
>> More Info and Purchase
Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers
and resistors
Publisher:
Business
Insights
Report Description
‘Evolving Trends in Biopharmaceutical Licensing’ is a report published
by Business Insights that provides a detailed analysis of licensing
strategies in the biopharmaceutical industry over the 2001-08 period.
This report examines the growth of the biopharmaceutical industry,
deal-making trend data, drivers and challenges facing biopharmaceutical
licensing, and profiles of biopharmaceutical licensing among leading
companies. The future prospects of the industry are assessed and the
potential impact of political/regulatory factors upon licensing and
alliances is identified. This report also investigates the influence
of the recent upsurge in M&A activity and provides recommendations on the
strategies that can sustain future growth.
>> More Info and Purchase
Technology Transfer Strategies: Maximizing the returns from new technologies
Publisher:
Business
Insights
Report Description
Technology transfer is a long-established part of early-stage research
within the pharmaceutical and biotechnology industries. Although
technology transfer offices have traditionally been associated with
inefficiency and a lack of commercial judgment, recent trends have shown
improvements in staffing, expertise and service levels. However, the
tech transfer function has recently suffered from ‘funding gaps’ for
promising new technologies. A clear disparity exists between current
service offerings and demand levels amongst investors/industry partners,
while the lack of an established model for effective technology transfer
function and significant regional variations are major obstacles to future
progress.
>> More Info and Purchase
Intellectual Property and Outsourcing in China: Minimizing risk whilst
maximizing return on investment
Publisher:
Business
Insights
Report Description
The industry for Pharmaceutical outsourcing in China has experienced
high growth in recent years. Today, in addition to an increasing
number of traditional Chinese pharmaceutical companies becoming involved in
the full scope of contract manufacturing services, more and more new,
professional outsourcing service providers have emerged. The majority
of Chinese CROs and CMOs are small in size and limited in service capability
growth, however a growing number are matching the service levels provided by
their foreign counterparts. Meanwhile, an increasing number of
multinational CROs/CMOs have recently entered the Chinese market, and the
number of pharma and biotech companies, both large multinationals and
start-ups, conducting outsourcing activities in China has risen
dramatically.
>> More Info and Purchase
Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide
Publisher:
Datamonitor
Introduction
Datamonitor's Pharmaceuticals - BRIC (Brazil, Russia, India, China)
Industry Guide is an essential resource for top-level data and analysis
covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry.
The report includes easily comparable data on market value, volume,
segmentation and market share, plus full five year market forecasts.
It examines future problems, innovations and potential growth areas within
the market.
>> More Info and Purchase
Pharmaceuticals: China Industry Guide
Publisher:
Datamonitor
Introduction
Datamonitor's Pharmaceuticals: China Industry Guide is an essential
resource for top-level data and analysis covering the China Pharmaceuticals
industry. It includes detailed data on market size and segmentation,
textual analysis of the key trends and competitive landscape, and profiles
of the leading companies. This incisive report provides expert
analysis with distinct chapters for Biotechnology, Generics, OTC
Pharmaceuticals and Pharmaceuticals.
>> More Info and Purchase
Divestment Strategies: Pharma is divesting in order to grow
Publisher:
Datamonitor
Introduction
Pharmaceutical companies are now divesting non-core assets such as
medical devices and manufacturing plants in an effort to cut costs and focus
on core strategies, primarily drug development. However, while some
Pharma companies are narrowing their focus, targeting specific disease areas
for future growth, others are taking a broader approach in an effort to
spread risk and return on investment.
Scope
• Provides an introduction to divestment strategies in the
current financial climate, including the drivers and resistors of divesting
a company asset
• Offers recommendations on how the best divest to and how to
optimize the divestment process
• Examines divesture deal trends and values during Q1 2006 to Q3
2008
• Provides case study analysis of the divesture deal trends
during Q1 2006 to Q3 2008
>> More Info and Purchase
Biotech Financing in the Credit Crisis: Strategies for a radically
altered landscape
Publisher:
Datamonitor
Introduction
Since the financial meltdown, the relationship between Pharma and
Biotech has been turned on its head. Previously, pharma companies had
no choice but to license Biotech drugs at high prices in order to fill their
sparse late stage pipelines.
Scope
• Overview licensing trends up until the credit crisis
• Strategic analysis of biotech's funding crisis
• Insight into how the biopharma market is expected to change and
adapt
• Recommendations and potential financial solutions for biotech
>> More Info and Purchase
